Can Weight-Loss Injection Pens Help Reduce Alcohol Consumption?

Recent research has investigated the potential of GLP-1 analogs (medications used to treat type 2 diabetes and obesity, such as semaglutide, for example) in modulating alcohol consumption. Preclinical studies indicate a reduction in alcohol intake and in the reward response associated with substance use, while clinical evidence remains preliminary and heterogeneous. This text briefly presents what science currently knows about the mechanisms involved, the results available so far, and the main challenges in applying these drugs to the treatment of alcohol use disorder (AUD).

Research on the biological effects of GLP-1 analogs (semaglutide, tirzepatide, liraglutide)—the so-called “weight-loss injection pens”—on alcohol consumption has become a relevant scientific field due to the global impact of alcohol use disorder, which is associated with high morbidity and mortality worldwide.¹² Although these glucagon-like peptide-1 receptor agonists (GLP-1RAs) were originally developed to treat type 2 diabetes and obesity, studies suggest that these medications may also act on neurobiological circuits involved in regulating the reward system, generating interest in their role in addictive behaviors.¹ ²

Preclinical studies conducted in recent years have demonstrated reduced alcohol consumption in animal models, while more recent clinical research has evaluated the translational feasibility of these findings.³ ⁴ Clinical and social interest in this field is further reinforced by the limited effectiveness and low adherence rates of currently available pharmacological therapies for alcohol use disorders, as well as by the high relapse rates observed even after treatment.⁵ ⁶

However, the main challenge lies in the still limited understanding of the biological mechanisms and clinical efficacy of GLP-1 analogs in reducing alcohol consumption, particularly in humans.⁷ ⁸ Although preclinical findings are consistent and promising, results from clinical trials remain heterogeneous and, in many cases, preliminary, with evidence of benefit restricted to specific subgroups, such as individuals with obesity.⁵ ⁹

The literature also presents inconsistencies regarding potential neuropsychiatric adverse effects, as well as differences among the various GLP-1 receptor agonists in modulating behaviors associated with alcohol consumption.¹ ¹⁰ These uncertainties highlight a knowledge gap limited by the scarcity of large-scale randomized clinical trials, incomplete understanding of additional mechanisms involved, and variability in findings across different patient profiles.⁷ ¹¹ ¹²

How Do GLP-1 Analogs Work?

GLP-1 analogs, or GLP-1 receptor agonists (GLP-1RAs), act through integrated mechanisms involving peripheral metabolic effects and central modulation of neural circuits. Physiologically, GLP-1 is an intestinal hormone released in response to food intake, promoting glucose-dependent insulin secretion, inhibiting glucagon release, delaying gastric emptying, and reducing food intake—mechanisms that support its use in treating type 2 diabetes and obesity. Evidence indicates that GLP-1 receptors also exert effects in the central nervous system, either by crossing the blood-brain barrier or through vagus nerve–mediated pathways, acting in regions involved in energy homeostasis, motivation, and reward.¹³ ¹⁴

GLP-1 receptors are distributed in brain areas such as the hypothalamus, brainstem, ventral tegmental area, and nucleus accumbens, where their activation modulates mesolimbic dopaminergic neurotransmission and reduces the reinforcing value of natural stimuli and psychoactive substances. In the context of addictive behaviors, preclinical studies show that GLP-1 signaling is associated with reduced hedonic response, decreased reward-seeking behavior, and lower alcohol consumption. Although additional mechanisms—such as modulation of neuroinflammation and stress systems—have been proposed, their clinical relevance in humans has yet to be established.¹³ ¹⁴

Final Considerations

In summary, GLP-1 analogs emerge as a potentially promising pharmacological strategy for the treatment of alcohol use disorder, given their ability to modulate neural circuits involved in reward, motivation, and substance-seeking behavior. Preclinical evidence demonstrates reduced alcohol consumption and attenuation of hedonic response (immediate reward), providing a plausible mechanistic basis for their therapeutic potential.

However, the clinical application of GLP-1 receptor agonists in the treatment of alcohol use disorder should still be considered experimental. Human studies show heterogeneous and generally preliminary results, with potential benefits possibly limited to specific subgroups, and uncertainties remaining regarding long-term safety and differences among drugs within this class. Therefore, consolidating this approach depends on large-scale randomized clinical trials that can define its efficacy, safety, and more precise clinical indications.

References:

1. Carminati, M., Tondello, M., Concina, A., Olgiati, P., & Zanardi, R. (2025). Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: A systematic review of potential benefits and risks. International Clinical Psychopharmacologynull, . https://doi.org/10.1097/yic.0000000000000595
2. O'Farrell, M., Almohaileb, F. I., & Roux, C. W. L. (2025). Glucagon‐like peptide‐1 analogues reduce alcohol intake. Diabetes, Obesity and Metabolismnull, . https://doi.org/10.1111/dom.16152
3. Fink‐Jensen, A., Wörtwein, G., Wörtwein, G., Wörtwein, G., Ptito, M., Wörtwein, G., Wörtwein, G., Wörtwein, G., & Ptito, M. (2024). Effect of the glucagon-like peptide-1 (glp-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys. Psychopharmacologynull, . https://doi.org/10.1007/s00213-024-06637-2
4. Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Koob, G. F., Roberto, M., Vendruscolo, L. F., & Leggio, L. (2023). The glucagon-like peptide-1 (glp-1) analogue semaglutide reduces alcohol drinking and modulates central gaba neurotransmission.. JCI insight, 8 (12), . https://doi.org/10.1172/jci.insight.170671
5. Klausen, M. K., Jensen, M. E., Møller, M., Dous, N. L., Jensen, A. Ø., Zeeman, V. A., Johannsen, C., Lee, A. M., Thomsen, G., Macoveanu, J., Fisher, P. M., Gillum, M. P., Jørgensen, N., Bergmann, M. L., Poulsen, H. E., Becker, U., Holst, J. J., Benveniste, H., Volkow, N. D., ... Fink-Jensen, A. (2022). Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI insight, 7 (19), . https://doi.org/10.1172/jci.insight.159863
6. Köhne, S., Hillemacher, T., Glahn, A., & Bach, P. (2024). Emerging drugs in phase ii and iii clinical development for the treatment of alcohol use disorder.. Expert Opinion on Emerging Drugsnull, . https://doi.org/10.1080/14728214.2024.2342951
7. Bruns, V. N., Tressler, E. H., Vendruscolo, L. F., Leggio, L., & Farokhnia, M. (2024). Iuphar review - glucagon-like peptide-1 (glp-1) and substance use disorders: An emerging pharmacotherapeutic target. Pharmacological researchnull, 107312-107312. https://doi.org/10.1016/j.phrs.2024.107312
8. Klausen, M. K., Knudsen, G. M., Vilsbøll, T., & Fink-Jensen, A. (n.d.). Effects of glp-1 receptor agonists in alcohol use disorder.. https://doi.org/10.1111/bcpt.70004
9. Richards, J. R., Dorand, M. F., Royal, K., Mnajjed, L., Paszkowiak, M., & Simmons, W. K. (2023). Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss. The Journal of Clinical Psychiatrynull, . https://doi.org/10.4088/jcp.23m15068
10. Oesterle, T., & Ho, M. (2025). Glucagon-like peptide-1 receptor agonists: A new frontier in treating alcohol use disorder. Brain Sciences, 15 (7), 702-702. https://doi.org/10.3390/brainsci15070702
11. Lähteenvuo, M., Tiihonen, J., Solismaa, A., Tanskanen, A. O., Mittendorfer‐Rutz, E., & Taipale, H. (2024). Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatrynull, . https://doi.org/10.1001/jamapsychiatry.2024.3599
12. Alves, G. A. M., Teranishi, M., Ortega, A. C. T. D. C. G., James, F., & Arachchige, A. S. P. M. (2025). Mechanisms of glp-1 in modulating craving and addiction: Neurobiological and translational insights. Medical sciences, 13 (3), 136-136. https://doi.org/10.3390/medsci13030136
13. Vallöf N, Aranäs E, Colvin L, et al. A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder. Acta Neuropsychiatrica. 2025. https://pubmed.ncbi.nlm.nih.gov/39969054/
14. Farokhnia M, Tazare J, Pince CL, et al. GLP-1 receptor agonists for the treatment of alcohol use disorder. Journal of Clinical Investigation. 2025.
    https://pubmed.ncbi.nlm.nih.gov/40309769/